Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
44,162,869
-
Total 13F shares
-
27,161,835
-
Share change
-
-26,120
-
Total reported value
-
$39,111,943
-
Price per share
-
$1.44
-
Number of holders
-
45
-
Value change
-
+$249,044
-
Number of buys
-
12
-
Number of sells
-
30
Institutional Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) as of Q3 2025
As of 30 Sep 2025 Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) had 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 27,161,835 shares of stock of the company.
Largest 10 holders included ORBIMED ADVISORS LLC, BAKER BROS. ADVISORS LP, MILLENNIUM MANAGEMENT LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, RENAISSANCE TECHNOLOGIES LLC, ACADIAN ASSET MANAGEMENT LLC, MORGAN STANLEY, BlackRock, Inc., and TWO SIGMA ADVISERS, LP.
This table shows 45 institutional shareholders of the security as of 30 Sep 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.